Abstracts

393 – Single-Cell Analysis Identifies Broad Immune Alterations Despite ART-Induced Viral Suppression

Background While antiretroviral therapy (ART) effectively suppresses HIV/SIV plasma viremia, it does not eradicate the virus. Understanding antiviral responses and transcriptional dynamics under ART suppression, including changes elicited by incompletely resolved viremia, are crucial to developing effective cure strategies. The simian immunodeficiency virus (SIV) macaque model offers a highly controlled system capable of characterizing these…

450 – Genome-Wide Associated Variants of Neurocognitive Disorder Among People With and Without HIV

Background An important factor that increases susceptibility to neurocognitive disorder (NCI) or dementia in people with HIV (PWH) is divergence in host genetics. However, prior studies have been limited by small sample sizes and overrepresentation of the Caucasian population and young adults. This study aims to identify and compare the host genetic factors associated with cognitive impairment…

459 – APOBEC3-Mediated Editing of HIV Transcripts Protects Brain Injury in ART-Suppressed Individuals

Background Despite sustained viral suppression with antiretroviral therapy (ART), brain injury remains common in people with HIV. We previously reported that short HIV-1 RNA transcripts in CSF CD4⁺ T cells from virally suppressed individuals were associated with worse brain injury, but the underlying mechanisms remain unclear. To investigate this, we analyzed peripheral viral reservoirs in…

492 – Population PK and Exposure-Response Analysis of Orally Administered VH4011499 in People With HIV-1

Background VH4011499 (VH-499) is an HIV-1 capsid inhibitor currently in development as a long-acting antiretroviral agent for HIV-1. Here we describe VH-499 PK and its exposure-HIV-1 RNA response relationship to inform target exposures and dose selection for future clinical studies. Methods Data were analyzed from 2 phase 1 studies in participants without HIV where VH-499…

498 – Noninvasive Sample Types as Reliable Alternatives to Lesion Swabs for Molecular Diagnosis of Mpox

Background The current gold standard for diagnosing Mpox involves molecular testing of lesion swabs, which, although highly sensitive, is invasive and often challenging to obtain given the disease’s diverse clinical presentations. During the 2024 Mpox outbreak in Uganda, we assessed the diagnostic performance of three non-invasive specimen types: saliva, urine, and anal swabs, against paired…

226 – Interferome Profiling Links IFNα5-Mucin-1 Axis to HIV-1 Pathogenesis

Background Chronic HIV-1 infection is characterized by persistent immune activation that contributes to comorbidities among people with HIV-1 (PWH). Although type I interferons (IFN-I) are essential for antiviral immunity, sustained IFN-I activity has been implicated in immune dysfunction and disease progression. IFN-I comprises 13 IFNα subtypes and IFNβ, but their relative contributions to HIV-1 pathogenesis…

527 – Outcomes for Individuals Who Initiate CAB+RPV LA in OPERA With Viral Loads ≥50 vs <50 copies/mL

Background Cabotegravir + rilpivirine long-acting (CAB+RPV LA) is the only complete LA regimen approved for treatment-experienced people with HIV with viral loads (VL) <50 copies/mL (c/mL). This analysis described demographics, clinical characteristics, and virologic outcomes in individuals on CAB+RPV LA stratified by VL at initiation. Methods Treatment-experienced adults who initiated CAB+RPV LA from 21JAN2021-31DEC2024 in OPERA were stratified…